Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease

Annals of Neurology

Volumn 68, Issue 4, 2010, Pages 446-453

  Leinonen, Ville ^a   Koivisto, Anne M ^a,b   Savolainen, Sakari ^a   Rummukainen, Jaana ^c   Tamminen, Juuso N ^a   Tillgren, Tomi ^a   Vainikka, Sannakaisa ^a   Pyykkö, Okko T ^a   Mölsä, Juhani ^a   Fraunberg, Mikael ^a   Jääskeläinen, Juha E ^a   Soininen, Hilkka ^a,b   Rinne, Jaakko ^a   Alafuzoff, Irina ^b,d  

^a Kuopio University Hospital Finland   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN BIOPSY; CLINICAL EVALUATION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; FEMALE; FOLLOW UP; FRONTAL CORTEX; HEART VENTRICLE PRESSURE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NORMOTENSIVE HYDROCEPHALUS; PREDICTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; BIOPSY; BRAIN CORTEX; FINLAND; LONGITUDINAL STUDY; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOPSY; CEREBRAL CORTEX; COGNITION DISORDERS; FEMALE; FINLAND; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 78149478511     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22100     Document Type: Article

References (30)

1. Braak H, Braak E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239 259.
2. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389 404.
3. Thal DR, Rum U, Orantes M, Braak H., Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791 1800.
4. Braak H, Braak E., Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18: 351 357.
5. Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004; 62: 925 931.
6. Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia. N Engl J Med 2009; 360: 2302 2309.
7. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734 746.
8. Perrin RJ, Fagan AM, Holtzman DM., Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009; 461: 916 922.
9. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132: 1355 1365.
10. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009; 73: 294 301.
11. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302: 385 393.
12. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009; 66: 382 389.
13. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009; 8: 619 627.
14. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306 319.
15. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630 1645.
16. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of β-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008; 65: 304 309.
17. Warren JD, Schott JM, Fox NC, et al. Brain biopsy in dementia. Brain 2005; 128: 2016 2025.
18. Devito EE, Pickard JD, Salmond CH, et al. The neuropsychology of normal pressure hydrocephalus (NPH). Br J Neurosurg 2005; 19: 217 224.
19. Relkin N, Marmarou A, Klinge P, et al. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery 2005; 57: S4 S16.
20. McGirt MJ, Woodworth G, Coon AL, et al. Diagnosis, treatment, and analysis of long-term outcomes in idiopathic normal-pressure hydrocephalus. Neurosurgery 2005; 57: 699 705.
21. Savolainen S, Paljarvi L, Vapalahti M., Prevalence of Alzheimer's disease in patients investigated for presumed normal pressure hydrocephalus: a clinical and neuropathological study. Acta Neurochir (Wien) 1999; 141: 849 853.
22. Golomb J, Wisoff J, Miller DC, et al. Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response. J Neurol Neurosurg Psychiatry 2000; 68: 778 781.
23. Holm A, Savolainen S, Alafuzoff I., Brain biopsy prior to treatment of Alzheimer's disease. Minim Invasive Neurosurg 2003; 46: 161 164.
24. Savolainen S, Hurskainen H, Paljarvi L, et al. Five-year outcome of normal pressure hydrocephalus with or without a shunt: predictive value of the clinical signs, neuropsychological evaluation and infusion test. Acta Neurochir (Wien) 2002; 144: 515 523.
25. Folstein MF, Folstein SE, McHugh PR., Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189 198.
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
27. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939 944.
28. Alafuzoff I, Pikkarainen M, Arzberger T, et al. Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathol 2008; 115: 533 546.
29. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA., The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009; 66: 200 208.
30. Rafii MS, Aisen PS., Recent developments in Alzheimer's disease therapeutics. BMC Med 2009; 7: 7.